A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Authors

Benjamin R. Tan, Washington University School of Medicine in St. Louis
et al

Journal

British Journal of Cancer

Publication Date

2017

Volume

116

Issue

5

Inclusive Pages

575-583

Document Type

Open Access Publication

DOI

10.1038/bjc.2017.10

Rights and Permissions

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Johanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, Richard S Finn, Zev A Wainberg, Daniel A Laheru, Colin D Weekes, Benjamin R Tan, Gazala N Khan, Mark M Zalupski, Jeffrey R Infante, Suzanne Jones, Kyriakos P Papadopoulos, Anthony W Tolcher, Renae E Chavira, Janna L Christy-Bittel, Emma Barrett, and Amita Patnaik. British Journal of Cancer (2017) 116 (5), 575–583 | doi: 10.1038/bjc.2017.10 Copyright The Author(s) named above 2017. https://www.nature.com/articles/bjc201710 This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Recommended Citation

Tan, Benjamin R. and et al, "A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor." British Journal of Cancer. 116, 5. 575-583. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5792